Recent Quarter Total Invested
$560.61 M
Recent Quarter Institutional Ownership Percentage
104.71%
Total Invested of Last Quarter
$568.21 M
Ownership Percentage of Last Quarter
110.66%
KalVista Pharmaceuticals, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| VR ADVISER, LLC | 11/14/2024 | 6.25 M | $72.37 M | 0.00% | 13.52% |
| TANG CAPITAL MANAGEMENT LLC | 11/14/2024 | 4.32 M | $50.04 M | 2.43% | 9.35% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 11/14/2024 | 4.21 M | $48.78 M | 0.48% | 9.11% |
| VESTAL POINT CAPITAL, LP | 11/14/2024 | 4.00 M | $46.32 M | 73.91% | 8.65% |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 11/15/2024 | 3.69 M | $42.71 M | 0.00% | 7.98% |
| CAPITAL WORLD INVESTORS | 11/13/2024 | 3.37 M | $39.07 M | 4.54% | 7.30% |
| BLACKROCK FUNDING, INC. /DE | 11/13/2024 | 3.06 M | $35.46 M | 100.00% | 6.62% |
| BOXER CAPITAL, LLC | 11/14/2024 | 1.59 M | $18.41 M | 0.00% | 3.44% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 11/14/2024 | 1.42 M | $16.44 M | -30.74% | 3.07% |
| GREAT POINT PARTNERS LLC | 11/13/2024 | 1.30 M | $15.05 B | -2.92% | 2.81% |
| STATE STREET CORP | 11/14/2024 | 1.27 M | $14.73 M | 68.11% | 2.75% |
| BIOIMPACT CAPITAL LLC | 11/13/2024 | 896,915 | $10.39 M | 1.70% | 1.94% |
| EMERALD ADVISERS, LLC | 10/29/2024 | 835,988 | $9.68 M | 29.83% | 1.81% |
| GEODE CAPITAL MANAGEMENT, LLC | 11/12/2024 | 830,984 | $9.62 M | 3.07% | 1.80% |
| DAFNA CAPITAL MANAGEMENT LLC | 11/14/2024 | 723,678 | $8.38 M | -10.32% | 1.57% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 10/29/2024 | 650,980 | $7.54 M | 22.97% | 1.41% |
| WOODLINE PARTNERS LP | 11/14/2024 | 608,253 | $7.04 M | 304.26% | 1.32% |
| DIMENSIONAL FUND ADVISORS LP | 11/07/2024 | 607,036 | $7.03 M | 13.47% | 1.31% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 11/14/2024 | 574,558 | $6.65 M | 2.44% | 1.24% |
| SATURN V CAPITAL MANAGEMENT LLC | 11/14/2024 | 556,489 | $6.44 M | -50.69% | 1.20% |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 11/13/2024 | 431,232 | $5.32 M | -7.86% | 0.93% |
| JEFFERIES FINANCIAL GROUP INC. | 11/14/2024 | 375,000 | $4.34 M | 114.29% | 0.81% |
| FIRST TURN MANAGEMENT, LLC | 11/07/2024 | 355,000 | $4.11 M | -66.49% | 0.77% |
| ROSALIND ADVISORS, INC. | 10/30/2024 | 303,864 | $3.52 M | -10.10% | 0.66% |
| MORGAN STANLEY | 11/14/2024 | 297,402 | $3.44 M | -12.16% | 0.64% |
| READYSTATE ASSET MANAGEMENT LP | 11/14/2024 | 180,000 | $2.08 M | 100.00% | 0.39% |
| QUBE RESEARCH & TECHNOLOGIES LTD | 11/14/2024 | 178,608 | $2.07 M | 503.63% | 0.39% |
| NAN FUNG GROUP HOLDINGS LTD | 11/13/2024 | 154,522 | $1.79 M | -29.53% | 0.33% |
| UBS OCONNOR LLC | 11/14/2024 | 135,552 | $1.57 M | 10.24% | 0.29% |
| GOLDMAN SACHS GROUP INC | 11/14/2024 | 134,041 | $1.55 M | -37.04% | 0.29% |
| CITADEL ADVISORS LLC | 11/14/2024 | 127,249 | $1.47 M | 576.07% | 0.28% |
| WELLINGTON MANAGEMENT GROUP LLP | 11/14/2024 | 117,923 | $1.37 M | 40.35% | 0.26% |
| RUSSELL INVESTMENTS GROUP, LTD. | 11/13/2024 | 115,992 | $1.34 M | 47.42% | 0.25% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 11/12/2024 | 110,720 | $1.28 M | 0.11% | 0.24% |
| BANK OF NEW YORK MELLON CORP | 11/12/2024 | 105,611 | $1.22 M | -22.12% | 0.23% |
| CITADEL ADVISORS LLC | 11/14/2024 | 98,000 | $1.13 M | 910.31% | 0.21% |
| ZIMMER PARTNERS, LP | 11/14/2024 | 95,704 | $1.11 M | 52.63% | 0.21% |
| D. E. SHAW & CO., INC. | 11/14/2024 | 89,929 | $1.04 M | -10.13% | 0.19% |
| BIRCHVIEW CAPITAL, LP | 11/14/2024 | 82,000 | $949,560 | 78.26% | 0.18% |
| NUVEEN ASSET MANAGEMENT, LLC | 11/14/2024 | 80,443 | $931,530 | 0.00% | 0.17% |
| BARCLAYS PLC | 11/19/2024 | 67,222 | $778,000 | 418.49% | 0.15% |
| CLARIVEST ASSET MANAGEMENT LLC | 11/12/2024 | 57,096 | $672,591 | 0.00% | 0.12% |
| STATE OF WISCONSIN INVESTMENT BOARD | 11/14/2024 | 54,468 | $630,739 | -10.35% | 0.12% |
| BANK OF AMERICA CORP /DE/ | 11/14/2024 | 52,694 | $610,196 | -15.70% | 0.11% |
| RHUMBLINE ADVISERS | 11/12/2024 | 50,279 | $582,221 | -5.54% | 0.11% |
| RAFFERTY ASSET MANAGEMENT, LLC | 11/13/2024 | 43,830 | $507,551 | 100.00% | 0.09% |
| UBS GROUP AG | 11/14/2024 | 43,429 | $502,908 | 223.95% | 0.09% |
| SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 11/07/2024 | 40,863 | $473,194 | 0.00% | 0.09% |
| ALLIANCEBERNSTEIN L.P. | 11/14/2024 | 40,020 | $463,432 | -5.72% | 0.09% |
| TWO SIGMA ADVISERS, LP | 11/14/2024 | 38,322 | $443,769 | -39.29% | 0.08% |
KalVista Pharmaceuticals, Inc.institutional Ownership - Frequently Asked Questions
-
Who are the largest shareholders of KALV shares?
During the previous two years, 143 institutional investors and hedge funds held shares of KalVista Pharmaceuticals, Inc.. The most heavily invested institutionals were:
VR Adviser, LLC: 6.25 M
TANG CAPITAL MANAGEMENT LLC: 4.32 M
SUVRETTA CAPITAL MANAGEMENT, LLC: 4.21 M
Vestal Point Capital, LP: 4 M
Frazier Life Sciences Management, L.P.: 3.69 M
Capital World Investors: 3.37 M
-
What percentage of KalVista Pharmaceuticals, Inc. stock is owned by institutional investors?
104.71% of KalVista Pharmaceuticals, Inc. stock is owned by institutional investors.
-
How much institutional buying is happening at KALV ?
Institutional investors have bought a total of 49.59 M shares in the last 24 months. This purchase volume represents approximately $503.85 M in transactions.